Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
This article was originally published in The Pink Sheet Daily
Executive Summary
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.